Drug Interactions

Drug Interactions title pageDid you see the Canadian Pharmacists Association’s recent release about “Pharmacy in Canada”? It states that pharmacists are “increasingly being recognized as the medication management experts of the health care team” and as such are in an excellent position to identify, manage, and monitor drug interaction issues.

As oncology pharmacists, we know that one of the key needs of cancer patients is the avoidance and/or management of drug interactions related to anticancer therapies. Identification and management of potential and actual drug interactions can help to minimize adverse events and maximize the intended impact of cancer treatments, supportive care agents, and pharmacotherapy for additional co-morbidities.

CAPhO’s new Drug Interactions Program, the second installment of Oncology Practise Essentials, consists of a mixture of online independent study and an in-person workshop. You begin with the basics (Phase 1), then put that learning to the test by working through progressively difficult case studies (Phase 2), accumulating into an accredited in-person workshop (Phase 3) that will be held in conjunction with the CAPhO Conference 2018.

Phase 1Phase 1: BCCA Drug Interactions

The BC Cancer Agency’s “Drug Interactions” course was written and reviewed by pharmacists and incorporates the unique perspective of oncology pharmacy practice. It is accessible to CAPhO members and non-members who are health care professionals at no charge.

Access Phase 1: BCCA Drug Interactions

Phase 2Phase 2: "Choose Your Own Adventure"

At your own pace, work through 3 drug interaction cases, from simple to complex. The cases replicate common oncology drug interactions seen in practice that can have a variety of correct (or somewhat correct) management strategies. You will be asked to make a series of decisions including developing a recommendation and determining how best to implement your recommendation. 

Members - Access Phase 2: "Choose Your Own Adventure" at no charge. More details are coming soon.

Non-members - Become a member for access to Drug Interactions and the myriad of other benefits of membership or pay $20.00 to access Phase 2 cases. More details are coming soon.

Phase 3Phase 3: Live Workshop

The Live Workshop will be held in Ottawa during the afternoon of May 3, 2018, in conjunction with CAPhO Conference 2018.

In small groups, you will work through 4 drug interaction cases with the support of expert facilitators. The cases will be typical of clinically relevant drug interactions you will encounter in oncology pharmacy practice. You and your group will make a series of decisions including interpretation of the drug interaction resource information, development of a pharmaceutical care plan including a recommendation, clinical rationale, communication of your plan, and creation of a patient follow up and/or monitoring plan.

There will only be 24 spots available at the Live Workshop… and we are seeking CCCEP accreditation.

Visit the Drug Interactions Workshop page to learn more and to register. 

The Live Workshop is accessible to members and non-members for a fee.

Learning Objectives

The learner will:

  1. Examine and discuss the mechanisms (or mechanism theories) of common drug interactions seen in oncology practice to gain deeper knowledge of their clinical significance
  2. Evaluate and scrutinize the readily available drug interaction resources commonly used in practice to improve their application to patient care in practice
  3. Formulate optimal therapeutic plans through a systematic process, critical thinking, and clinical judgment to best manage and monitor oncology drug interactions
  4. Demonstrate effective communication of drug interaction management plans to support implementation, collaboration, and ongoing continuity of care
  5. Be encouraged to develop confidence and professional leadership within the context of drug interactions management

Contributors

Drug Interactions is an educational initiative that is a product of the efforts, resources and time of many people. The following CAPhO members supported the creation of this program.
 
Phase 1:
CAPhO would like to acknowledge the BC Cancer Agency in allowing Oncology Pharmacists access to its online “Drug Interactions Module,” which is Phase 1 of this three-phased Drug Interactions Program. We would especially like to thank Lynne Nakashima and Rhonda Kalyn for their support.
 
Phase 2:
The following CAPhO Members were involved in Phase 2 as Authors and Reviewers:
  • Beverly Dawson, BScPharm, BCPS, PharmD, Clinical Pharmacist in Oncology, Vitalité Health Network, New Brunswick
  • Jennifer Jupp, BScPharm, BCOP, Clinical Practice Leader, Hematology, Oncology, Blood and Marrow Transplant, Pharmacy Services, Alberta Health Services, Alberta
  • Nicole MacDonald, BScPharm, ACPR, Clinical Pharmacist, Dr. H. Bliss Murphy Cancer Centre, Eastern Health, Newfoundland
  • Tiffany Nguyen, BScPharm, ACPR, BCOP, Clinical Pharmacist, Bone Marrow Transplant Program, The Ottawa Hospital, Ontario
  • Danica Wasney, BScPharm, ACPR, BCOP, Clinical Pharmacist, Provincial Oncology Drug Program, CancerCare Manitoba, Manitoba
  • Jason Wentzell, BScPharm, ACPR, BCOP, Clinical Pharmacist, Medical Oncology, The Ottawa Hospital, Ontario
Phase 3:
The following CAPhO Members were involved in Phase 3 as Authors, Reviewers, Facilitators and Facilitator Manual Creators:
 
Authors:
  • Maria Anwar, BScPharm, ACPR, Clinical Practice Leader, Alberta Health Services, Alberta
  • Mark Diachinsky, BScPharm, Clinical Practice Leader, North Zone, Pharmacy Services, Alberta Health Services, Alberta
  • Erin Francis, BSc, BScPharm, ACPR, Pharmacist-Blood and Marrow Transplant and Gynecologic Oncology, Pharmacy Department, The Ottawa Hospital, Ontario
  • Iryna Knyazevych, BSc, BScPharm, PharmD, Pharmacy Educator, Cross Cancer Institute, Alberta Health Services, Alberta
Reviewers:
  • Melanie Danilak, BScPharm, ACPR, MEd, Pharmacy Clinical Practice Leader, Alberta Health Services, Alberta
  • Marcel Romanick, BScPharm, Clinical Practice Leader, Pharmacy Services, Alberta Health Services, Alberta
Facilitators:
  • Tara Leslie, BSP, BCOP, Clinical Pharmacist and Clinical Assistant Professor, Tom Baker Cancer Centre, and Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Alberta
  • Glenn Myers, BScPharm, ACPR, Clinical Oncology Pharmacist, Ambulatory Oncology, Horizon Health Network, New Brunswick
  • Tiffany Nguyen, BScPharm, ACPR, BCOP, Clinical Pharmacist, Bone Marrow Transplant Program, The Ottawa Hospital, Ontario
  • Jason Wentzel, BScPharm, ACPR, BCOP, Clinical Pharmacist, Medical Oncology, The Ottawa Hospital, Ontario
Facilitator Manual Creators:
  • Jennifer Jupp, BScPharm, BCOP, Clinical Practice Leader, Hematology, Oncology, Blood and Marrow Transplant, Pharmacy Services, Alberta Health Services, Alberta
  • Tara Leslie, BSP, BCOP, Clinical Pharmacist and Clinical Assistant Professor, Tom Baker Cancer Centre, and Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Alberta
  • Glenn Myers, BScPharm, ACPR, Clinical Oncology Pharmacist, Ambulatory Oncology, Horizon Health Network, New Brunswick
Drug Interactions Task Force Members
  • Glenn Myers (Chair)
  • Beverly Dawson
  • Carlo DeAngelis
  • Jennifer Jupp
  • Iryna Knyazevych
  • Tara Leslie
  • Sally Waignein
  • Melanie Danilak (past member)
Education Pharmacist Advanced Committee
 
Support
The project support team consisted of:
  • Sea to Sky Meeting Management Inc, Administrative Support
  • Mark Stephens, Windward Design Group, Graphic Designer

Disclaimer

The Canadian Association of Pharmacy in Oncology’s (CAPhO) Drug Interactions Program has been designed to provide a general overview of oncology drug pharmacology and therapeutics. It is NOT intended to be a comprehensive reference and as such it does NOT provide detailed explanations of mechanisms of action, descriptions of all drug indications, or an in-depth review of all possible adverse effects or drug interactions. The information contained in the Drug Interactions Program is not intended to be used to direct patient care decisions. It is important to utilize appropriate comprehensive resources, applicable primary literature and clinical judgement when making decisions regarding patient care.

CAPhO is not liable for any information provided in the content of the Drug Interactions Program. CAPhO hereby disclaims all liability for any claims, losses or damages in connection with use or application of these materials.

The content of the Drug Interactions cases is for educational purposes only and may contain some copyrighted materials from biology textbooks, medical periodicals, articles and web sites. Wherever possible, the authors of such materials have been contacted for permission to use and/or adapt such materials; a reference or link is provided to the original source.

This educational initiative was funded by CAPhO. It has received no financial or in-kind support from any commercial or other organization.

CAPhO would like to acknowledge the BC Cancer Agency in allowing oncology pharmacists access to its online “Drug Interactions Module,” which is Phase 1 of this three-phased Drug Interactions Program.